BridgeBio Oncology Therapeutics (BBOT) versus Its Competitors Head to Head Survey - American Market News
Author: ABMN Staff
Description: Read BridgeBio Oncology Therapeutics (BBOT) versus Its Competitors Head to Head Survey at American Market News
Keywords: BridgeBio Oncology Therapeutics,NASDAQ:BBOT,BBOT,Financial Service,comparison,review,stock comparison,stock analysis
Date: 2026-06-12T05:27:30+0000

Skip to main content

# BridgeBio Oncology Therapeutics (BBOT) versus Its Competitors Head to Head Survey

Posted by ABMN Staff on Jun 12th, 2026

Share on Twitter
Share on Facebook
Share on LinkedIn
Share on Stocktwits

BridgeBio Oncology Therapeutics (NASDAQ:BBOT – Get Free Report) is one of 324 publicly-traded companies in the “Investment Offices” industry, but how does it contrast to its competitors? We will compare BridgeBio Oncology Therapeutics to related businesses based on the strength of its earnings, profitability, institutional ownership, dividends, risk, valuation and analyst recommendations.

Get BridgeBio Oncology Therapeutics alerts:

## Analyst Recommendations

This is a summary of current ratings and target prices for BridgeBio Oncology Therapeutics and its competitors, as reported by MarketBeat.com.

| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score
BridgeBio Oncology Therapeutics | 1 | 0 | 4 | 0 | 2.60
BridgeBio Oncology Therapeutics Competitors | 341 | 90 | 129 | 2 | 1.63

BridgeBio Oncology Therapeutics presently has a consensus price target of $25.00, indicating a potential upside of 235.12%. As a group, “Investment Offices” companies have a potential upside of 35.66%. Given BridgeBio Oncology Therapeutics’ stronger consensus rating and higher possible upside, equities research analysts clearly believe BridgeBio Oncology Therapeutics is more favorable than its competitors.

## Institutional & Insider Ownership

54.9% of BridgeBio Oncology Therapeutics shares are owned by institutional investors. Comparatively, 48.4% of shares of all “Investment Offices” companies are owned by institutional investors. 24.4% of BridgeBio Oncology Therapeutics shares are owned by insiders. Comparatively, 29.1% of shares of all “Investment Offices” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

## Volatility & Risk

BridgeBio Oncology Therapeutics has a beta of 0.29, indicating that its stock price is 71% less volatile than the S&P 500. Comparatively, BridgeBio Oncology Therapeutics’ competitors have a beta of 0.41, indicating that their average stock price is 59% less volatile than the S&P 500.

## Valuation and Earnings

This table compares BridgeBio Oncology Therapeutics and its competitors gross revenue, earnings per share (EPS) and valuation.

| Gross Revenue | Net Income | Price/Earnings Ratio
BridgeBio Oncology Therapeutics | N/A | -$134.04 million | -3.64
BridgeBio Oncology Therapeutics Competitors | $75.02 million | -$160.87 million | -387.21

BridgeBio Oncology Therapeutics’ competitors have higher revenue, but lower earnings than BridgeBio Oncology Therapeutics. BridgeBio Oncology Therapeutics is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

## Profitability

This table compares BridgeBio Oncology Therapeutics and its competitors’ net margins, return on equity and return on assets.

| Net Margins | Return on Equity | Return on Assets
BridgeBio Oncology Therapeutics | N/A | N/A | N/A
BridgeBio Oncology Therapeutics Competitors | 697.12% | -3.34% | -1.94%

## Summary

BridgeBio Oncology Therapeutics beats its competitors on 8 of the 13 factors compared.

## BridgeBio Oncology Therapeutics Company Profile

(Get Free Report)

We are a blank check company incorporated as a Cayman Islands exempted company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. Throughout this prospectus, we will refer to this as our initial business combination. We have not selected any specific business combination target and we have not, nor has anyone on our behalf, engaged in any substantive discussions, directly or indirectly, with any potential business combination target with respect to an initial business combination with us. While we may pursue a business combination target in any business or industry, we intend to focus on healthcare or healthcare related industries, which can benefit from the expertise and capabilities of our management team in order to create long-term shareholder value. Our sponsor is an affiliate of Cormorant, a leading life sciences focused investment firm with over $2 billion in assets under management as of December 31, 2022. Our Chairperson and Chief Executive Officer, Bihua Chen, founded Cormorant and is the managing member of Cormorant. Since its inception in 2013, Cormorant has focused on the healthcare industry and invests, throughout their growth cycle, in companies that discover and develop therapeutic drugs or medical technology. Cormorant is an active life-science investor with investments in over 100 privately held, life science-focused companies over this period. Of these investments, over 50 have completed initial public offerings. Notable successes include Prometheus Biosciences, Inc., Turning Point Therapeutics, Inc., and MyoKardia, Inc., each of which has been acquired for more than $4 billion. Other notable successes include BridgeBio Pharma Inc. and Apellis Pharmaceuticals Inc., each of which is a public company with a market capitalization greater than $1 billion. Our executive offices are located at 200 Clarendon Street, 52nd Floor, Boston, MA.

Receive News & Ratings for BridgeBio Oncology Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BridgeBio Oncology Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

## You might be interested in:

Aviva PLC Acquires 59,782 Shares of Gilead Sciences, Inc. $GILD
First Financial Bankshares Inc Buys 136,871 Shares of CocaCola Company $KO
Graetz Wealth LLC Buys New Stake in Applied Materials, Inc. $AMAT
Banco BTG Pactual S.A. Acquires 46,564 Shares of Taiwan Semiconductor Manufacturing Company Ltd. $TSM
Buckley Wealth Management LLC Raises Position in Oracle Corporation $ORCL
16,528 Shares in Vanguard S&P 500 ETF $VOO Bought by Graetz Wealth LLC